stockrow
Friday 6 November 2026
Export SYRE’s income statement to Excel — free account
Spyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.
- EPS
- −624.8%
- Free cash flow
- −108.8%
Quarter to September 2026, against a year earlier
103.23
6.64
+6.87%
Follow SYRE
Alert me
Spyre Therapeutics, Inc. (SYRE) Revenue
Spyre Therapeutics, Inc.'s revenue for fiscal 2023 was $886.0K, down 62.0% from $2.3M in fiscal 2022. Over the past ten years it has ranged from $886.0K (fiscal 2023) to $18.7M (fiscal 2021) — the current reading is the lowest in ten years. Spyre Therapeutics, Inc. ranks 310th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2023 | $886.0K | (61.96%) |
| FY2022 | $2.3M | (87.57%) |
| FY2021 | $18.7M | 381.97% |
| FY2018 | $3.9M | (25.30%) |
| FY2017 | $5.2M | 12.47% |
| FY2016 | $4.6M | (23.94%) |
| FY2015 | $6.1M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Dec 2023 | $0.00 | — |
| Jun 2023 | $688.0K | 247.47% |
| Mar 2023 | $198.0K | 17.86% |
| Dec 2022 | $168.0K | (3.45%) |
| 19 more quarters | Free account |
Against its own ten years
Low $886.0K
High $18.7M
Ten-year median
$4.6M
Current reading's percentile
14
Revenue against peers
| Company | Revenue |
|---|---|
| MDGL Madrigal Pharmaceuticals, Inc. compare | $1.4B |
| CAI Caris Life Sciences,�Inc. compare | $1.0B |
| TGTX TG Therapeutics, Inc. compare | $799.5M |
| KRYS Krystal Biotech, Inc. compare | $470.0M |
| TWST Twist Bioscience Corporation compare | $431.8M |
| PTGX Protagonist Therapeutics, Inc. compare | $282.0M |
| IBRX ImmunityBio, Inc. compare | $165.8M |
| CYTK Cytokinetics, Incorporated compare | $113.3M |
| SYRE Spyre Therapeutics, Inc. | $1.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on SYRE
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement